Analyst Downgrade Signal: ACAD from Buy to Underperform by Jefferies
Price Target: $25>>10
Report Date: 06-21-2022
Symbol: ACAD - ACADIA Pharmaceuticals Inc.
Sector: Healthcare
Industry: Biotechnology
Analyst Downgrade Signal: ACAD from Buy to Underperform by Jefferies
Price Target: $25>>10
ACADIA Pharmaceuticals Inc. (ACAD)
3611 Valley Centre Dr Ste 300
San Diego, CALIFORNIA 92130
Phone: 18585582871
Website: http://www.acadia-pharm.com
CEO: Mr. Stephen Davis
NASDAQ, Nasdaq Global Select
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
best stock trading signals, best stock trading signals, daily stock signals, stock option trading signals
Good stock signals have been found on this server. That is all we know.
+1 (407) 559-7228